GALDERMA
Galderma announced today positive topline results from the phase III READY-3 clinical trial investigating the use of RelabotulinumtoxinA for the treatment of glabellar lines (frown lines) and lateral canthal lines (crow’s feet), either alone (single-area) or simultaneously. The study met its co-primary endpoints, demonstrating that a single dose of RelabotulinumtoxinA significantly improves both frown lines and crow’s feet, when treated alone or simultaneously, with long duration of effect for six months.1 These and other results from the READY phase III clinical trial program, as well as from Galderma’s broad and innovative aesthetics portfolio, will be presented at the TOXINS 2024 International Conference in Berlin, held from January 17-20, 2024.
“We’re looking forward to sharing the latest updates from our world-leading injectable aesthetics portfolio at TOXINS 2024, particularly first data from our phase III READY-3 trial. These results build on those previously seen in the READY-1 and READY-2 trials, further reinforcing RelabotulinumtoxinA’s ability to provide long-lasting improvement for frown lines and crow’s feet when treated simultaneously.”
BALDO SCASSELLATI SFORZOLINI, M.D., Ph.D.
GLOBAL HEAD OF R&D
GALDERMA
The READY clinical trial program is composed of four phase III trials which enrolled more than 1,900 participants. READY-3 is a phase III randomized, double-blind, placebo-controlled trial designed to assess the safety and efficacy, as measured by aesthetic improvement, of RelabotulinumtoxinA in patients with moderate to severe frown lines or crow’s feet, either administered as a single-area treatment or simultaneously on both frown lines and crow’s feet, when compared to placebo. The trial met its co-primary endpoints, with patients and investigators reporting at least a two-grade improvement in line severity after single-area treatment of frown lines (71%) or crow’s feet (45%) and simultaneous treatment (72% frown lines and 55% crow’s feet), compared to placebo at one month (p<0.001).1
Investigator-reported response rates at one month were high, with 94-96% reporting none or mild frown lines when treated alone or simultaneously with crow’s feet, compared to placebo (2%, p<0.001), and 79-84% reporting none or mild crow’s feet when treated alone or simultaneously with frown lines, compared to placebo (20%, p<0.001). The median time of return to baseline line severity on both investigator- and patient-assessed scales was approximately six months after single-area (24-25 weeks) or simultaneous treatment (25-27 weeks), reinforcing previous results demonstrating the long duration of effect of RelabotulinumtoxinA. Patient satisfaction was high, with up to 91% reporting satisfaction with simultaneous treatment at one month. RelabotulinumtoxinA was well tolerated with low rates of treatment-related adverse events reported (4-9% compared to 5% for placebo); there were no serious treatment-related adverse events.1
“Patients often want their aesthetic look to last longer or to receive treatment on multiple facial areas simultaneously, and practitioners want to deliver consistent results for their patients. These new data highlight the ability of RelabotulinumtoxinA to address all these key needs for frown lines and crow’s feet, while also being a ready-to-use formulation that’s easy to administer.”
DR. VINCE BERTUCCI, M.D.
CO-DIRECTOR, DERMATOLOGIC LASER SURGERY & AESTHETIC DERMATOLOGY FELLOWSHIP, UNIVERSITY OF TORONTO, CANADA
These results further reinforce the positive safety, efficacy and long duration of effect data observed in the READY-1 and READY-2 trials, which – together with recent phase IIIB results – also demonstrated RelabotulinumtoxinA’s rapid onset of action on frown lines and crow’s feet as early as day 1.2-5 Data from the READY-1 and READY-2 studies will be presented at the TOXINS 2024 conference, highlighting that:2,3
- Both studies met their primary endpoints, with significantly higher responses than placebo after one month for both frown lines and crow’s feet.
- Results showed rapid onset of action, with over a third of patients seeing results on day 1 for frown lines (39%) and crow’s feet (34%), and demonstrated long duration of effect for six months.
RelabotulinumtoxinA is currently under investigation by Galderma and is not approved for any indication in any jurisdiction.
At the conference, Galderma will also present data from its broad and innovative neuromodulator portfolio, including:
- Results from the phase IV STAR study demonstrating the innovative science of Alluzience® (abobotulinumtoxinA solution) for the treatment of frown lines. In 81% of the treatment sessions, the investigators preferred Alluzience over onabotulinumtoxinA. The majority of patients maintained aesthetic improvement in frown lines and reported high satisfaction, including a natural and refreshed look, throughout six months.6
- Results from a phase IV non-interventional study investigating the real-world use of Dysport® (abobotulinumtoxinA) for the treatment of frown lines in 250 patients in China, reinforcing the long-term duration results and providing further evidence of Dysport use in clinical practice.7
Additionally, a Galderma-sponsored educational symposium on Alluzience will be chaired by Dr. Magdalena Korwin and Dr. Christoph Martschin, on Friday, January 19, from 3:35 – 4:05PM CET.
More details on Galderma’s scientific presentations at TOXINS 2024 can be found here.
About RelabotulinumtoxinA (QM1114)
Developed by Galderma, RelabotulinumtoxinA is a highly-active, innovative, complex-free, and ready-to-use liquid botulinum toxin A with a proprietary strain and manufactured using a unique state-of-the-art process. It is designed as a ready-to-use liquid solution, avoiding the traditional requirement to reconstitute from powder and eliminating variability, errors and risks associated with reconstitution, which would be expected to improve the consistency of results. RelabotulinumtoxinA is currently being investigated globally by Galderma, to expand its neuromodulator portfolio as part of the broadest Injectable Aesthetics portfolio on the market.
About Alluzience®
Alluzience (abobotulinumtoxinA solution) is the first ready-to-use BoNT-A liquid neuromodulator formulation to be introduced in Europe. Alluzience is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines seen at maximum frown in adult patients under 65 years, when the severity of these lines has an important psychological impact on the patient. It should only be administered by a physician with appropriate qualifications and expertise in this treatment using the required equipment. Dosing and treatment intervals depend on assessment of the individual patient’s response. The treatment interval should be no more frequent than every three months. For more information, please see the Summary of Product Characteristics.8
Alluzience is a product under license from Ipsen. Alluzience is a registered trademark of Ipsen. Galderma has an exclusive license from Ipsen to develop, promote and distribute Alluzience in the approved indication in Europe.
About Dysport®
Dysport (abobotulinumtoxinA) is a prescription injection indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with procerus and corrugator muscle activity in adult patients less than 65 years of age, the treatment of adults with cervical dystonia, the treatment of upper limb spasticity in adults, and the treatment of lower limb spasticity in pediatric patients two years of age and older.9 Dysport is also marketed as Azzalure in the European Union for the treatment of glabellar lines and lateral canthal lines. Dysport has more than 30 years of clinical experience globally for therapeutic indications and 13 years for aesthetics indications, with extensive clinical evidence of safety and efficacy. It is licensed for aesthetic indications in more than 85 markets worldwide, Dysport is one of the world’s leading brands of aesthetic neuromodulators with over 100 million treatments delivered in the aesthetics indications to date.
Dysport is a product under license from Ipsen and is manufactured by them. Since 2009, Galderma and Ipsen have had a strategic partnership under which Galderma has promoted and distributed Ipsen’s botulinum toxin type A products in aesthetic indications. The Ipsen-Galderma strategic partnership now covers China, the United States, Europe and the Middle East, Australia, South Korea, Canada, Brazil, Argentina and certain other countries. Ipsen continues to promote Dysport within certain therapeutic indications in countries around the world. For more information on Ipsen, visit www.ipsen.com.
About Galderma
Galderma is the emerging pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market though Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.
References:
- Bertucci V, et al. Efficacy and Safety of a Novel Formulation Liquid Botulinum Toxin, RelabotulinumtoxinA, when used for Combination Treatment of Glabellar and Lateral Canthal Lines. Abstract presented at TOXINS 2024.
- Solish N, et al. Treatment of Moderate-to-Severe Glabellar Lines with RelabotulinumtoxinA, an Investigational Liquid Botulinum Toxin: Clinical Efficacy and Safety Results from the READY-1 Phase III trial. Abstract presented at TOXINS 2024.
- Ablon G, et al. Treatment of Lateral Canthal Lines with RelabotulinumtoxinA, an Investigational Liquid Botulinum Toxin: Clinical Efficacy and Safety Results from the READY-2 Phase III Trial. Abstract presented at TOXINS 2024.
- Galderma data on file: initial results of the phase IIIb 43QM2106 trial
- Galderma data on file: initial results of the phase IIIb 43QM2107 trial
- Persson C, et al. Patient and Investigator Treatment Experience with Ready-to-Use AbobotulinumtoxinA Solution Versus Powder BotulinumtoxinA for Treatment of Glabellar Lines. Abstract presented at TOXINS 2024.
- Persson C, et al. A Real-World Study of Patient and Physician Satisfaction with AbobotulinumtoxinA Treatment of Glabellar Lines in Chinese Patients. Abstract presented at TOXINS 2024.
- Alluzience® Summary of Product Characteristics, 2023.
- Dysport® Summary of Product Characteristics, 2022.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240116024729/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Cyclic Materials Secures USD $75M Series C Funding to Fast-Track Local and Resilient Rare Earths Supply at Global Scale23.1.2026 13:00:00 CET | Press release
New equity investment will accelerate deployment of resilient, locally anchored rare earths recycling infrastructure enabling new streams of heavy rare earths supply for AI, robotics, defense and advanced manufacturing critical to the future of Western industry Cyclic Materials today announced it has closed an over-subscribed USD $75 million Series C equity round, its largest to date, scaling up operations across the US and Europe and accelerating Canada-based research and development footprint. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260123519008/en/ Cyclic Materials’ Mesa, Arizona site, the very first scale-up of a commercial plant for recycling and local production of rare earths in the US, with a focus on heavy and light rare earth magnets. The recycling of magnet-containing end-of-life (EOL) scrap and magnet production waste is the fastest way to the production of magnet rare earth elements (REEs) in Western coun
SLB Announces Fourth-Quarter and Full-Year 2025 Results, Increases Dividend and Commits to Return More Than $4 Billion to Shareholders in 202623.1.2026 12:50:00 CET | Press release
Fourth-quarter revenue of $9.75 billion increased 9% sequentially and 5% year on year Fourth-quarter GAAP EPS of $0.55 increased 10% sequentially and decreased 29% year on year Fourth-quarter EPS, excluding charges and credits, of $0.78 increased 13% sequentially and declined 15% year on year Fourth-quarter net income attributable to SLB of $824 million increased 12% sequentially and decreased 25% year on year Fourth-quarter adjusted EBITDA of $2.33 billion increased 13% sequentially and decreased 2% year on year Fourth-quarter cash flow from operations was $3.01 billion and free cash flow was $2.29 billion Board approved a 3.5% increase in quarterly cash dividend to $0.295 per share Full-year revenue of $35.71 billion decreased 2% year on year Full-year GAAP EPS of $2.35 decreased 24% year on year Full-year EPS, excluding charges and credits, of $2.93 decreased 14% year on year Full-year net income attributable to SLB of $3.37 billion decreased 24% year on year Full-year adjusted EBIT
“And I Chose to Live” The Blind Sailor Mitsuhiro Iwamoto Takes the Stage at WEF23.1.2026 09:00:00 CET | Press release
- “HIRO’s CHOICE”: A Solo, Non-Stop Crossing of the Pacific Ocean- Mitsuhiro Iwamoto, a blind Japanese sailor based in San Diego, delivered a speech at the World Economic Forum Annual Meeting 2026 on January 21 (local time). He is undertaking the world’s first solo, non-stop trans-Pacific crossing by a blind person as part of the “Blind Sailor Single-Handed Pacific Crossing Project 2027.” WEF URL: https://www.weforum.org/ This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260121469502/en/ Hiro Iwamoto / Global Keynote Speaker, First Totally Blind Sailor to Cross the Pacific In the spring of 2027, he will attempt a solo, non-stop trans-Pacific crossing, sailing a 28-foot yacht single-handedly from San Diego on the U.S. West Coast to Amakusa, Kumamoto Prefecture, Japan, without making any port calls. Project URL: https://hiros-choice.com/ The theme of his speech was “Sailing Through Barriers.” He spoke about how, since losing his
BitGo Holdings fejrer sin børsnotering på New York Stock Exchange23.1.2026 03:52:00 CET | Pressemeddelelse
BitGo Holdings, Inc. ("BitGo", "virksomheden", "vi"), en virksomhed inden for digital infrastruktur til aktiver, fejrer i dag sin lancering på New York Stock Exchange ("NYSE") som et børsnoteret selskab under tickersymbolet "BTGO". Medlemmer af BitGos ledelsesteam vil i dag kl. 09:30 ET ringe med åbningsklokken på NYSE. "I dag markerer et afgørende øjeblik for BitGo," udtaler Mike Belshe, administrerende direktør og medstifter af BitGo. "Vores indtræden på de offentlige markeder vil gøre det muligt for os yderligere at accelerere det finansielle systems overgang til en gennemsigtig og troværdig digital aktivøkonomi, samtidig med at vi fortsat kan levere enestående sikkerheds-, depot- og likviditetsløsninger til vores kunder. Vi er overbeviste om, at potentialet forude er stort, og at vi er unikt positioneret til at hjælpe institutioner med at gå fremtiden i møde." Belshe fortsætter: "Jeg er utroligt stolt af den virksomhed, vi har opbygget, og dybt taknemmelig for vores teams hårde arb
Tinaba with Banca Profilo Strengthens Its Global Positioning and Launches Digital Payments in the Chinese Mainland with Alipay+23.1.2026 02:41:00 CET | Press release
Through the “Pay Worldwide with Alipay+” feature available in the App, users can pay in the Chinese mainland at over 80 million merchants Tinaba with Banca Profilo announces the launch of digital payments in the Chinese mainland through the extension of its strategic partnership with Alipay+, Ant International’s global wallet gateway solution, bringing a simple, cashless and local payment experience to Italian travellers in the world’s largest digital market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260122062969/en/ Matteo Arpe, President of Tinaba with Banca Profilo, announces the expanded partnership with Alipay+ in Milan, Italy Starting today, users can pay in the Chinese mainland at over 80 million merchants simply by scanning a QR code directly from the Tinaba App. This innovation is particularly significant in a country where digital payments are the everyday standard and cash is increasingly less used. The servi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom